Inhibition of c-MYC with involvement of ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and its derivatives in killing leukemia cells

Oncotarget

Volumn 6, Issue 36, 2015, Pages 38934-38951

  Zhao, Qiaoli ^a   Assimopoulou, Andreana N ^b   Klauck, Sabine M ^c   Damianakos, Harilaos ^d   Chinou, Ioanna ^d   Kretschmer, Nadine ^e   Rios, José Luis ^f   Papageorgiou, Vassilios P ^b   Bauer, Rudolf ^e   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF ATHENS   (Greece)

^e UNIVERSITY OF GRAZ   (Austria)

^f UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Acute leukemia; AKT pathway; c MYC; ERK JNK MAP kinases; Shikonin and its derivatives

Indexed keywords

10058 F4; 10074 G5; 2 METHYLBUTYRYLALKANNIN; 2 METHYLBUTYRYLSHIKONIN; ACETYLALKANNIN; ACETYLSHIKONIN; ALKANNIN; BETA BETA DIMETHYLACRYLSHIKONIN; BETA HYDROXYISOVALERYLALKANNIN; BETA HYDROXYISOVALERYLSHIKONIN; DEOXYSHIKONIN; ISOBUTYRYLALKANNIN; ISOBUTYRYLSHIKONIN; ISOVALERYLSHIKONIN; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROPRIONYLALKANNIN; PROTEIN INHIBITOR; PROTEIN KINASE B; SHIKONIN; SHIKONIN DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; TERACRYLALKANNIN; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MYC PROTEIN, HUMAN; NAPHTHOQUINONE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING ASSAY; CCRF CEM CELL LINE; CELL KILLING; CEM ADR5000 CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC50; JURKAT CELL LINE; LEUKEMIA CELL; LEUKEMIA CELL LINE; MICROARRAY ANALYSIS; MOLECULAR DOCKING; MOLT4 CELL LINE; PROTEIN EXPRESSION; RNA HYBRIDIZATION; UPREGULATION; WESTERN BLOTTING; DRUG EFFECTS; GENETICS; LEUKEMIA; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; U-937 CELL LINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKEMIA; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NAPHTHOQUINONES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; U937 CELLS;

EID: 84948784158     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5380     Document Type: Article

References (68)

1. Basha R, Sabnis N, Heym K, Bowman WP, Lacko AG. Targeted nanoparticles for pediatric leukemia therapy. Frontiers in oncology. 2014; 4:101.
2. Annesley CE, Brown P. Novel agents for the treatment of childhood acute leukemia. Therapeutic advances in hematology. 2015; 6:61-79.
3. Jacoby E, Chien CD, Fry TJ. Murine models of acute leukemia: important tools in current pediatric leukemia research. Frontiers in oncology. 2014; 4:95.
4. Pui CH, Gajjar AJ, Kane JR, Qaddoumi IA, Pappo AS. Challenging issues in pediatric oncology. Nature reviews Clinical oncology. 2011; 8:540-549.
5. Pan XN, Chen JJ, Wang LX, Xiao RZ, Liu LL, Fang ZG, Liu Q, Long ZJ, Lin DJ. Inhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiation. Plos One. 2014; 9:e105381.
6. Zajac-Kaye M. Myc oncogene: a key component in cell cycle regulation and its implication for lung cancer. Lung cancer. 2001; 34:S43-46.
7. Tansey WP. Mammalian MYC Proteins and Cancer. New Journal of Science. 2014; 2014:27.
8. Delgado MD, Albajar M, Gomez-Casares MT, Batlle A, Leon J. MYC oncogene in myeloid neoplasias. Clinical&translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2013; 15:87-94.
9. Delgado MD, Leon J. Myc roles in hematopoiesis and leukemia. Genes&cancer. 2010; 1:605-616.
10. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. The Journal of experimental medicine. 1988; 167:353-371.
11. Varmus HE. The molecular genetics of cellular oncogenes. Annual review of genetics. 1984; 18:553-612.
12. Fauriat C, Olive D. AML drug resistance: c-Myc comes into play. Blood. 2014; 123:3528-3530.
13. Xia B, Tian C, Guo S, Zhang L, Zhao D, Qu F, Zhao W, Wang Y, Wu X, Da W, Wei S, Zhang Y. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia. Leukemia research. 2015; 39:92-99.
14. Kiessling A, Sperl B, Hollis A, Eick D, Berg T. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chemistry&biology. 2006; 13:745-751.
15. Yap JL, Chauhan J, Jung K-Y, Chen L, Prochownik EV, Fletcher S. Small-molecule inhibitors of dimeric transcription factors: Antagonism of protein-protein and protein-DNA interactions. MedChemComm. 2012; 3:541-551.
16. Hammoudeh DI, Follis AV, Prochownik EV, Metallo SJ. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. Journal of the American Chemical Society. 2009; 131:7390-7401.
17. Yap JL, Wang H, Hu A, Chauhan J, Jung KY, Gharavi RB, Prochownik EV, Fletcher S. Pharmacophore identification of c-Myc inhibitor 10074-G5. Bioorganic&medicinal chemistry letters. 2013; 23:370-374.
18. Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Advances in cancer research. 2010; 107:163-224.
19. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nature reviews Cancer. 2008; 8:976-990.
20. Marampon F, Ciccarelli C, Zani BM. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Molecular cancer. 2006; 5:31.
21. Papageorgiou VP, Assimopoulou AN, Couladouros EA, Hepworth D, Nicolaou KC. The Chemistry and Biology of Alkannin, Shikonin, and Related Naphthazarin Natural Products. Angewandte Chemie. International Edition 1999; 38:270-301.
22. Damianakos H, Kretschmer N, Syklowska-Baranek K, Pietrosiuk A, Bauer R, Chinou I. Antimicrobial and Cytotoxic Isohexenylnaphthazarins from Arnebia euchroma (Royle) Jonst. (Boraginaceae) Callus and Cell Suspension Culture. Molecules. 2012; 17:14310-14322.
23. Kretschmer N, Rinner B, Deutsch AJ, Lohberger B, Knausz H, Kunert O, Blunder M, Boechzelt H, Schaider H, Bauer R. Naphthoquinones from Onosma paniculata induce cell-cycle arrest and apoptosis in melanoma Cells. Journal of natural products. 2012; 75:865-869.
24. Zhao Q, Kretschmer N, Bauer R, Efferth T. Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib. Int J Cancer. 2015; 137:1446-1456.
25. Wiench B, Eichhorn T, Paulsen M, Efferth T. Shikonin Directly Targets Mitochondria and Causes Mitochondrial Dysfunction in Cancer Cells. Evid Based Complement Alternat Med. 2012; 2012:726025.
26. Zhu J, Blenis J, Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:6584-6589.
27. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell research. 2002; 12:9-18.
28. Gramling MW, Eischen CM. Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis. Cell death and differentiation. 2012; 19:1220-1227.
29. Plyta ZF, Li T, Papageorgiou VP, Mellidis AS, Assimopoulou AN, Pitsinos EN, Couladouros EA. Inhibition of topoisomerase I by naphthoquinone derivatives. Bioorganic&medicinal chemistry letters. 1998; 8:3385-3390.
30. Bieker R, Lerchenmuller C, Wehmeyer J, Serve HL, Mesters RM, Buchner T, Berdel WE. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia. Oncol Rep. 2003; 10:915-920.
31. Gorin NC, Estey E, Jones RJ, Levitsky HI, Borrello I, Slavin S. New Developments in the Therapy of Acute Myelocytic Leukemia. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2000; 69-89.
32. Jeong K-C, Ahn K-O, Yang C-H. Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrest. Molecular BioSystems. 2010; 6:1503-1509.
33. Sanchez-Duffhues G, Calzado MA, de Vinuesa AG, Appendino G, Fiebich BL, Loock U, Lefarth-Risse A, Krohn K, Munoz E. Denbinobin inhibits nuclear factor-kappaB and induces apoptosis via reactive oxygen species generation in human leukemic cells. Biochemical pharmacology. 2009; 77:1401-1409.
34. Thangapazham RL, Singh AK, Seth P, Misra N, Mathad VT, Raj K, Maheshwari RK. Shikonin analogue (SA) 93/637 induces apoptosis by activation of caspase-3 in U937 cells. Frontiers in bioscience: a journal and virtual library. 2008; 13:561-568.
35. Bretones G, Delgado MD, Leon J. Myc and cell cycle control. Biochimica et biophysica acta. 2015; 1849:506-516.
36. Heikkila R, Schwab G, Wickstrom E, Loke SL, Pluznik DH, Watt R, Neckers LM. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature. 1987; 328:445-449.
37. Wickstrom EL, Bacon TA, Gonzalez A, Freeman DL, Lyman GH, Wickstrom E. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proceedings of the National Academy of Sciences of the United States of America. 1988; 85:1028-1032.
38. Pattabiraman DR, Gonda TJ. Role and potential for therapeutic targeting of MYB in leukemia. Leukemia. 2013; 27:269-277.
39. Zhao L, Ye P, Gonda TJ. The MYB proto-oncogene suppresses monocytic differentiation of acute myeloid leukemia cells via transcriptional activation of its target gene GFI1. Oncogene. 2014; 33:4442-4449.
40. Kutok JL, Yang X, Folkerth R, Adra CN. Characterization of the expression of HTm4 (MS4A3), a cell cycle regulator, in human peripheral blood cells and normal and malignant tissues. J Cell Mol Med. 2011; 15:86-93.
41. Donato JL, Ko J, Kutok JL, Cheng T, Shirakawa T, Mao XQ, Beach D, Scadden DT, Sayegh MH, Adra CN. Human HTm4 is a hematopoietic cell cycle regulator. J Clin Invest. 2002; 109:51-58.
42. Piao JL, Cui ZG, Furusawa Y, Ahmed K, Rehman MU, Tabuchi Y, Kadowaki M, Kondo T. The molecular mechanisms and gene expression profiling for shikonin-induced apoptotic and necroptotic cell death in U937 cells. Chemico-biological interactions. 2013; 205:119-127.
43. Wada N, Kawano Y, Fujiwara S, Kikukawa Y, Okuno Y, Tasaki M, Ueda M, Ando Y, Yoshinaga K, Ri M, Iida S, Nakashima T, Shiotsu Y, Mitsuya H, Hata H. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells. International journal of oncology. 2015; 46:963-972.
44. Xuan Y, Hu X. Naturally-occurring shikonin analogues-a class of necroptotic inducers that circumvent cancer drug resistance. Cancer Lett. 2009; 274:233-242.
45. Thompson EB. The many roles of c-Myc in apoptosis. Annual review of physiology. 1998; 60:575-600.
46. Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene. 2008; 27:6462-6472.
47. Ayala-Torres S, Zhou F, Thompson EB. Apoptosis induced by oxysterol in CEM cells is associated with negative regulation of c-myc. Experimental cell research. 1999; 246:193-202.
48. Lerga A, Belandia B, Delgado MD, Cuadrado MA, Richard C, Ortiz JM, Martin-Perez J, Leon J. Down-regulation of c-Myc and Max genes is associated to inhibition of protein phosphatase 2A in K562 human leukemia cells. Biochem Biophys Res Commun. 1995; 215:889-895.
49. Kimura S, Maekawa T, Hirakawa K, Murakami A, Abe T. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res. 1995; 55:1379-1384.
50. Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Experimental hematology. 2006; 34:1480-1489.
51. Chen Y, Zheng L, Liu J, Zhou Z, Cao X, Lv X, Chen F. Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways. International immunopharmacology. 2014; 21:447-455.
52. Cheng YW, Chang CY, Lin KL, Hu CM, Lin CH, Kang JJ. Shikonin derivatives inhibited LPS-induced NOS in RAW 264.7 cells via downregulation of MAPK/NF-kappaB signaling. Journal of ethnopharmacology. 2008; 120:264-271.
53. Mao X, Yu CR, Li WH, Li WX. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell research. 2008; 18:879-888.
54. Ahn J, Won M, Choi JH, Kim YS, Jung CR, Im DS, Kyun ML, Lee K, Song KB, Chung KS. Reactive oxygen species-mediated activation of the Akt/ASK1/p38 signaling cascade and p21(Cip1) downregulation are required for shikonin-induced apoptosis. Apoptosis: an international journal on programmed cell death. 2013; 18:870-881.
55. Andujar I, Rios JL, Giner RM, Recio MC. Pharmacological properties of shikonin - a review of literature since 2002. Planta medica. 2013; 79:1685-1697.
56. McKeown MR, Bradner JE. Therapeutic strategies to inhibit MYC. Cold Spring Harbor perspectives in medicine. 2014; 4.
57. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes&development. 2000; 14:2501-2514.
58. Alarcon-Vargas D, Ronai Z. c-Jun-NH2 kinase (JNK) contributes to the regulation of c-Myc protein stability. The Journal of biological chemistry. 2004; 279:5008-5016.
59. Hofmann JW, Zhao X, De Cecco M, Peterson AL, Pagliaroli L, Manivannan J, Hubbard GB, Ikeno Y, Zhang Y, Feng B, Li X, Serre T, Qi W, Van Remmen H, Miller RA, Bath KG, et al. Reduced expression of MYC increases longevity and enhances healthspan. Cell. 2015; 160:477-488.
60. Rajagopalan V, Vaidyanathan M, Janardhanam VA, Bradner JE. Pre-clinical analysis of changes in intra-cellular biochemistry of glioblastoma multiforme (GBM) cells due to c-Myc silencing. Cellular and molecular neurobiology. 2014; 34:1059-1069.
61. Tan Y, Sementino E, Pei J, Kadariya Y, Ito TK, Testa JR. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice. Cancer biology&therapy. 2015; 16:580-588.
62. Arita K, Tsuzuki S, Ohshima K, Sugiyama T, Seto M. Synergy of Myc, cell cycle regulators and the Akt pathway in the development of aggressive B-cell lymphoma in a mouse model. Leukemia. 2014; 28:2270-2272.
63. Saeed M, Greten H, Efferth T. Collateral Sensitivity in Drug-Resistant Tumor Cells. Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Springer New York). Bonavida B. 2013; :187-211.
64. Eberwine J, Yeh H, Miyashiro K, Cao Y, Nair S, Finnell R, Zettel M, Coleman P. Analysis of gene expression in single live neurons. Proceedings of the National Academy of Sciences of the United States of America. 1992; 89:3010-3014.
65. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4:44-57.
66. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research. 2009; 37:1-13.
67. Clausen DM, Guo J, Parise RA, Beumer JH, Egorin MJ, Lazo JS, Prochownik EV, Eiseman JL. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. The Journal of pharmacology and experimental therapeutics. 2010; 335:715-727.
68. Kadioglu O, Fu Y, Wiench B, Zu Y, Efferth T. Synthetic cajanin stilbene acid derivatives inhibit c-MYC in breast cancer cells. Archives of toxicology. 2015. Feb 26. [Epub ahead of print]